BRPI0509552A - vacina de glicoproteìna mucinosa (muc-1) - Google Patents

vacina de glicoproteìna mucinosa (muc-1)

Info

Publication number
BRPI0509552A
BRPI0509552A BRPI0509552-2A BRPI0509552A BRPI0509552A BR PI0509552 A BRPI0509552 A BR PI0509552A BR PI0509552 A BRPI0509552 A BR PI0509552A BR PI0509552 A BRPI0509552 A BR PI0509552A
Authority
BR
Brazil
Prior art keywords
muc
formulation
glycoprotein vaccine
vaccine
mucinous glycoprotein
Prior art date
Application number
BRPI0509552-2A
Other languages
English (en)
Inventor
Michael B Longenecker
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of BRPI0509552A publication Critical patent/BRPI0509552A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

VACINA DE GLICOPROTEìNA MUCINOSA (MUC-1). A presente invenção fornece um método para o tratamento de um indivíduo que é portador de câncer, como carcinoma pulmonar de células não pequenas ou câncer de próstata, por administração àquele individuo de uma formulação baseada em MUC-l A formulação pode ser formulação de vacina lipossómica baseada em MUC-l.
BRPI0509552-2A 2004-04-01 2005-04-01 vacina de glicoproteìna mucinosa (muc-1) BRPI0509552A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55813904P 2004-04-01 2004-04-01
US57680404P 2004-06-04 2004-06-04
PCT/IB2005/002479 WO2005112546A2 (en) 2004-04-01 2005-04-01 Mucinous glycoprotein (muc-1) vaccine

Publications (1)

Publication Number Publication Date
BRPI0509552A true BRPI0509552A (pt) 2007-09-18

Family

ID=35428714

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509552-2A BRPI0509552A (pt) 2004-04-01 2005-04-01 vacina de glicoproteìna mucinosa (muc-1)

Country Status (15)

Country Link
US (2) US9173929B2 (pt)
EP (2) EP2524700B1 (pt)
JP (3) JP5590768B2 (pt)
CN (2) CN1997388B (pt)
AR (1) AR051350A1 (pt)
AU (1) AU2005244675B2 (pt)
BR (1) BRPI0509552A (pt)
CA (1) CA2562990A1 (pt)
DK (2) DK1737485T3 (pt)
ES (2) ES2478006T3 (pt)
HU (1) HUE027378T2 (pt)
PL (2) PL1737485T3 (pt)
PT (2) PT1737485E (pt)
TW (2) TW201204410A (pt)
WO (1) WO2005112546A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja) * 2005-06-28 2013-12-11 オンコセリオン インコーポレイテッド ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
AU2012268892B2 (en) * 2005-06-28 2016-05-26 Oncothyreon Inc. Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CN102256595A (zh) * 2008-12-17 2011-11-23 肿瘤防护公司 制备小粒径脂质体的方法
WO2011054359A2 (en) * 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
EP2560989B1 (en) 2010-04-19 2017-03-22 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
CN105193724A (zh) * 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗
PT2723363T (pt) 2011-06-24 2018-11-08 Nono Inc Terapia de combinação para isquemia
DE102011085695A1 (de) * 2011-11-03 2013-05-08 Jörg Pohl Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CN105283199A (zh) 2013-05-14 2016-01-27 默克专利股份公司 通过muc-1脂肽接种治疗肺癌的方法
CN105517566A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 用于治疗前列腺癌的组合物和疫苗
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110393797A (zh) * 2019-05-27 2019-11-01 南开大学 基于糖脂佐剂的糖肽疫苗的制备方法与应用
US11878057B2 (en) * 2020-12-11 2024-01-23 Trustees Of Boston University Immunomodulatory lipopolysaccharide compositions
WO2026011417A1 (en) * 2024-07-12 2026-01-15 The Hong Kong University Of Science And Technology Compositions and methods involving artificial poly (a) sequences

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
DE3683688D1 (de) 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
DK0478715T3 (da) 1989-06-23 1996-08-05 Liposome Co Inc Målrettede liposomer og fremgangsmåder til liposom-protein-kobling
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en) 1995-06-07 1996-12-19 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU734253B2 (en) 1996-03-20 2001-06-07 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
ATE273320T1 (de) 1996-04-11 2004-08-15 Univ British Columbia Fusogene liposomen
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
JP4480800B2 (ja) 1997-05-08 2010-06-16 オンコシリオン・インコーポレイテッド 活性化ｔ細胞および抗原パルス標識した抗原提示細胞を生成する方法
JPH11139961A (ja) 1997-11-06 1999-05-25 Taisho Pharmaceut Co Ltd リポソームの製造方法
EP1045688A1 (en) 1998-01-16 2000-10-25 Biomira Usa Inc. Lipomatrix preparation
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US6104536A (en) 1998-09-18 2000-08-15 3M Innovative Properties Company High efficiency polarization converter including input and output lenslet arrays
ATE397488T1 (de) 1998-11-13 2008-06-15 Heriot William A Vorrichtung zur herstellung von liposomen
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
DE60018761T2 (de) 1999-08-18 2006-02-02 Altarex Medical Corp., Edmonton Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
JP2003510094A (ja) 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
AU780577B2 (en) 1999-11-15 2005-04-07 Oncothyreon Inc. Synthetic Lipid-A analogs and uses thereof
WO2001070265A2 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
AU1999802A (en) * 2000-12-01 2002-06-11 Lawrence Boni Preparation of large liposomes by infusion into peg
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
EP2263465A1 (en) * 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalent conjugate vaccine for cancer
JP3760467B2 (ja) 2002-04-09 2006-03-29 ソニー株式会社 コンテンツ再生装置および方法、記録媒体、並びにプログラム
US20060069238A1 (en) 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7595195B2 (en) 2003-02-11 2009-09-29 The Regents Of The University Of California Microfluidic devices for controlled viscous shearing and formation of amphiphilic vesicles
US9198645B2 (en) 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja) 2005-06-28 2013-12-11 オンコセリオン インコーポレイテッド ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
CN103989633A (zh) 2005-07-27 2014-08-20 普洛体维生物治疗公司 制造脂质体的系统和方法
JP5126874B2 (ja) 2007-05-21 2013-01-23 国立大学法人神戸大学 リポソーム製剤の製造方法
CN102256595A (zh) 2008-12-17 2011-11-23 肿瘤防护公司 制备小粒径脂质体的方法

Also Published As

Publication number Publication date
PT1737485E (pt) 2014-08-22
JP2014177479A (ja) 2014-09-25
JP5590768B2 (ja) 2014-09-17
HUE027378T2 (en) 2016-10-28
JP2012092105A (ja) 2012-05-17
EP2524700B1 (en) 2015-10-28
DK2524700T3 (en) 2016-02-01
JP5868125B2 (ja) 2016-02-24
HK1109574A1 (en) 2008-06-13
WO2005112546A2 (en) 2005-12-01
WO2005112546A3 (en) 2006-05-04
JP2007530663A (ja) 2007-11-01
CN1997388A (zh) 2007-07-11
TW200538147A (en) 2005-12-01
PL2524700T3 (pl) 2016-04-29
PT2524700E (pt) 2016-02-29
TWI395591B (zh) 2013-05-11
CA2562990A1 (en) 2005-12-01
EP1737485A4 (en) 2008-09-03
AU2005244675B2 (en) 2011-07-21
CN103933556A (zh) 2014-07-23
CN1997388B (zh) 2014-03-26
ES2560808T3 (es) 2016-02-22
PL1737485T3 (pl) 2014-10-31
ES2478006T3 (es) 2014-07-18
AR051350A1 (es) 2007-01-10
EP1737485B1 (en) 2014-05-07
TW201204410A (en) 2012-02-01
EP2524700A1 (en) 2012-11-21
EP1737485A2 (en) 2007-01-03
DK1737485T3 (da) 2014-08-04
US9173929B2 (en) 2015-11-03
US20080131495A1 (en) 2008-06-05
US20160082093A1 (en) 2016-03-24
AU2005244675A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
BR112013008140A2 (pt) "compostos imidazotriazinona".
WO2005112546A3 (en) Mucinous glycoprotein (muc-1) vaccine
CR20120528A (es) Métodos para tratar el cáncer
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
AU2016262079A8 (en) Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
MX370662B (es) Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
BR112012011457A2 (pt) uso antitumoral de cabazitaxel.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112015005758A2 (pt) métodos para modular níveis de corticosterona em indivíduos psicologicamente estressados
CR20120202A (es) Métodos y composiciones para tratar cáncer
WO2008089397A3 (en) Adrb2 cancer markers
BR112014002141A2 (pt) crizotinib para uso no tratamento de câncer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
BR112016028641A2 (pt) ?método para tratar câncer?
BRPI0811387B8 (pt) kit de administração de um surfactante pulmonar
BR112014032728A2 (pt) uso de marcadores no diagnóstico e tratamento de câncer de próstata
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
WO2009032172A3 (en) Platinum compositions as treatment for oct-related cancers
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
BR112016001696A2 (pt) composições tópicas para o tratamento de sudorese excessiva e métodos de uso destas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]